{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:36:22Z","timestamp":1790368582663,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctrv.2026.103111","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:23:02Z","timestamp":1771374182000},"page":"103111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7569-9864","authenticated-orcid":false,"given":"Anna","family":"McCracken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia R.","family":"Grafinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon S.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ctrv.2026.103111_b0005","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103111_b0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1055-9965.EPI-17-1129","article-title":"Can we use survival data from cancer registries to learn about disease recurrence? The case of breast cancer","volume":"27","author":"Mariotto","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-022-06812-z","article-title":"Estimating the incidence of breast cancer recurrence using administrative data","volume":"198","author":"Habbous","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103111_b0020","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/bjc.2014.5","article-title":"Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics","volume":"110","author":"Colzani","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0025","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3747\/co.27.5769","article-title":"A population-based analysis of breast cancer incidence and survival by subtype in Ontario women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0035","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0040","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103111_b0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0050","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524879","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2022","volume":"17","author":"Ditsch","year":"2022","journal-title":"Breast Care"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0065","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. Published online June 1, 2023. doi:10.6004\/jnccn.2023.0031.","DOI":"10.6004\/jnccn.2023.0031"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0070","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7093","article-title":"Prognosis after pathologic complete response to neoadjuvant therapy in early-stage breast cancer: a population-based study","volume":"23","author":"Boman","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0075","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41556-018-0256-3","article-title":"Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models","volume":"21","author":"Keklikoglou","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.5410","article-title":"Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial","volume":"155","author":"Golshan","year":"2020","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-016-4006-6","article-title":"Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II\u2013III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)","volume":"160","author":"Golshan","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SLA.0000000000001417","article-title":"Impact of neoadjuvant chemotherapy in stage II\u2013III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)","volume":"262","author":"Golshan","year":"2015","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.25118","article-title":"Comparison of use of neoadjuvant systemic treatment for breast cancer and short-term outcomes before vs during the COVID-19 Era in Ontario, Canada","volume":"5","author":"Habbous","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials","volume":"19","author":"Asselain","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103111_b0105","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103111_b0115","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103111_b0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/curroncol31110484","article-title":"Guidance for Canadian breast cancer practice: national consensus recommendations for the systemic treatment of patients with HER2+ breast cancer in both the early and metastatic setting","volume":"31","author":"Manna","year":"2024","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103111_b0125","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103111_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002275","article-title":"Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape","volume":"21","author":"Ganesan","year":"2023","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00404-011-1954-2","article-title":"Trastuzumab clears HER2\/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients","volume":"285","author":"Rack","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103111_b0145","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2\u2013positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103111_b0150","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1200\/JCO.22.01816","article-title":"De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0155","doi-asserted-by":"crossref","unstructured":"Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial. Ann Oncol. Published online October 21, 2025. doi:10.1016\/j.annonc.2025.10.019.","DOI":"10.1016\/j.annonc.2025.10.019"},{"key":"10.1016\/j.ctrv.2026.103111_b0160","unstructured":"LBA1 presented at the ESMO Congress 2025, Presidential Simposium. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. Presented at: ESMO; Saturday, 18 October, 16:30-18:15."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0165","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1186\/s12885-023-11293-4","article-title":"Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis","volume":"23","author":"Cortes","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103111_b0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers17101635","article-title":"Programmed death-1 ligand 1 domain organization, signaling motifs, and interactors in cancer immunotherapy","volume":"17","author":"Escors","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103111_b0180","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","article-title":"Immunological differences between primary and metastatic breast cancer","volume":"29","author":"Szekely","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0190","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103111_b0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ctrv.2026.103111_b0200","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijbiomac.2021.03.075","article-title":"Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis\u2014new insight and futuristic vision","volume":"180","author":"Huang","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ctrv.2026.103111_b0205","first-page":"15","article-title":"Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters","author":"Gremmelspacher","year":"2025","journal-title":"Nat Genet Published online June 2"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103111_b0210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nbt.2576","article-title":"Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay","volume":"31","author":"Baccelli","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103111_b0215","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103111_b0220","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","article-title":"Association of circulating tumor cells with late recurrence of estrogen receptor\u2013positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sparano","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0225","doi-asserted-by":"crossref","first-page":"20949","DOI":"10.1038\/s41598-022-25609-0","article-title":"Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer","volume":"12","author":"Grigoryeva","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0230","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41591-024-03486-6","article-title":"Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial","volume":"31","author":"Kurzeder","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0235","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","article-title":"Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding","volume":"176","author":"Gkountela","year":"2019","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103111_b0240","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-17-0255","article-title":"Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant \u201cGeparquattro\u201d trial","volume":"23","author":"Riethdorf","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-016-4026-2","article-title":"Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer","volume":"161","author":"Wang","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0250","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc865","article-title":"Dissemination and growth of cancer cells in metastatic sites","volume":"2","author":"Chambers","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"7634","key":"10.1016\/j.ctrv.2026.103111_b0255","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature20785","article-title":"Early dissemination seeds metastasis in breast cancer","volume":"540","author":"Hosseini","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2007.12.003","article-title":"Systemic spread is an early step in breast cancer","volume":"13","author":"H\u00fcsemann","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103111_b0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-024-01293-9","article-title":"Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination","volume":"16","author":"Lawrence-Paul","year":"2024","journal-title":"Genome Med"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103111_b0270","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4161\/cc.5.16.2864","article-title":"Dormancy of solitary metastatic cells","volume":"5","author":"Townson","year":"2006","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0275","article-title":"Toronto workshop on late recurrence in estrogen receptor\u2013positive breast cancer: Part 1: late recurrence","volume":"3","author":"Dowling","year":"2019","journal-title":"Current Understanding, Clinical Considerations JNCI Cancer Spectr"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0280","article-title":"Toronto workshop on late recurrence in estrogen receptor-positive breast cancer: Part 2: approaches to predict and identify late recurrence, research directions","volume":"3","author":"Dowling","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41568-023-00642-x","article-title":"Targeting cancer cell dormancy","volume":"24","author":"Agudo","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103111_b0290","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-11-0207","article-title":"Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression","volume":"17","author":"Li","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0295","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41416-021-01514-7","article-title":"Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer","volume":"125","author":"J\u00f8rgensen","year":"2021","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0300","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10555-021-09968-0","article-title":"Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer","volume":"40","author":"Nelson","year":"2021","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0305","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-07-4491","article-title":"Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells","volume":"14","author":"Ladoire","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0310","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1186\/s12885-016-2732-0","article-title":"Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs\u00a0: a systematic review and meta-analysis","volume":"16","author":"Shou","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0315","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ctrv.2026.103111_b0320","doi-asserted-by":"crossref","unstructured":"Egelston CA, Avalos C, Tu TY, et al. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight. 4(19):e130000. doi:10.1172\/jci.insight.130000.","DOI":"10.1172\/jci.insight.130000"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0325","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103111_b0330","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/bioinformatics\/bty357","article-title":"Distinguishing prognostic and predictive biomarkers: an information theoretic approach","volume":"34","author":"Sechidis","year":"2018","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103111_b0335","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1177\/09622802251348183","article-title":"Response adaptive randomisation in clinical trials: current practice, gaps and future directions","volume":"34","author":"Wilson","year":"2025","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ctrv.2026.103111_b0340","first-page":"18","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","author":"Mittendorf","year":"2025","journal-title":"Nat Med Published online June 4"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0345","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1186\/s12885-024-12689-6","article-title":"Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0350","first-page":"1","article-title":"Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0360","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41523-025-00778-z","article-title":"Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer","volume":"11","author":"Nguyen","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0365","doi-asserted-by":"crossref","first-page":"14704","DOI":"10.1038\/s41598-020-71236-y","article-title":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","volume":"10","author":"Cavallone","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103111_b0370","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P2-11-26","article-title":"Abstract P2-11-26: the prognostic role of circulating tumor DNA after neoadjuvant chemotherapy in triple negative breast cancer with residual tumor","volume":"83","author":"Roseshter","year":"2023","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0375","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-24-3472","article-title":"Ultrasensitive detection and monitoring of circulating tumor DNA using Structural variants in early-stage breast cancer","volume":"31","author":"Elliott","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103111_b0380","unstructured":"ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence. American Association for Cancer Research (AACR). Accessed October 16, 2025. https:\/\/www.aacr.org\/about-the-aacr\/newsroom\/news-releases\/zest-trial-offers-insights-for-using-ctdna-to-predict-breast-cancer-recurrence\/."},{"key":"10.1016\/j.ctrv.2026.103111_b0385","article-title":"Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103111_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100230","article-title":"PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers","volume":"6","author":"Dumbrava","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103111_b0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158143","article-title":"Diagnostic accuracy of PIK3CA mutation detection by circulating free DNA in breast cancer: a meta-analysis of diagnostic test accuracy","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103111_b0400","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1878-0261.12540","article-title":"PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study","volume":"13","author":"Tzanikou","year":"2019","journal-title":"Mol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103111_b0405","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djy018","article-title":"Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis","volume":"110","author":"Bidard","year":"2018","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103111_b0410","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103111_b0415","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.515","article-title":"Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: results from the adjuvant SUCCESS a trial","volume":"36","author":"Janni","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0420","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clbc.2020.02.006","article-title":"Response assessment with molecular characterization of circulating tumor cells and plasma MicroRNA profiling in patients with locally advanced breast cancer during neoadjuvant chemotherapy","volume":"20","author":"Akkiprik","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0425","doi-asserted-by":"crossref","first-page":"43464","DOI":"10.1038\/srep43464","article-title":"Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis","volume":"7","author":"Yan","year":"2017","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103111_b0430","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-08-0030","article-title":"Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial","volume":"14","author":"Pierga","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0435","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10517-014-2514-0","article-title":"Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy","volume":"157","author":"Lavrov","year":"2014","journal-title":"Bull Exp Biol Med"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103111_b0440","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1158\/1078-0432.CCR-18-3888","article-title":"Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer","volume":"25","author":"Magbanua","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103111_b0445","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers14163949","article-title":"Does the presence of circulating tumor cells in high-risk early breast cancer patients predict the site of first metastasis\u2014results from the adjuvant success a trial","volume":"14","author":"Trapp","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103111_b0450","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.06.028","article-title":"Disseminated tumour cells from the bone marrow of early breast cancer patients: results from an international pooled analysis","volume":"154","author":"Hartkopf","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0455","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-022-06803-0","article-title":"Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study","volume":"198","author":"Magbanua","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0460","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.26202","article-title":"Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer","volume":"118","author":"Hall","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0465","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/bcr3242","article-title":"Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival","volume":"14","author":"Mathiesen","year":"2012","journal-title":"Breast Cancer Res BCR"},{"issue":"34","key":"10.1016\/j.ctrv.2026.103111_b0470","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2014.56.9327","article-title":"Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer","volume":"32","author":"Naume","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0475","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0480","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-023-01619-2","article-title":"The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy","volume":"25","author":"Wimberger","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0485","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/cancers14030635","article-title":"Neoadjuvant chemotherapy of patients with early breast cancer is associated with increased detection of disseminated tumor cells in the bone marrow","volume":"14","author":"Volmer","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-025-00760-9","article-title":"Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment","volume":"11","author":"Taurelli Salimbeni","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0495","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103111_b0500","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3892\/ol.2023.14028","article-title":"Prognostic relevance of tumor\u2011infiltrating lymphocytes in residual tumor tissue from patients with triple\u2011negative breast cancer following neoadjuvant chemotherapy: a systematic review and meta\u2011analysis","volume":"26","author":"Cao","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2026.103111_b0505","article-title":"Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis","volume":"20","author":"Gao","year":"2020","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103111_b0510","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0515","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.clbc.2023.12.011","article-title":"Prognostic value and distribution pattern of tumor infiltrating lymphocytes and their subsets in distant metastases of advanced breast cancer","volume":"24","author":"Sun","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103111_b0520","unstructured":"Tumor infiltrating lymphocytes (TIL) predict response to neoadjuvant chemotherapy in breast cancer: A systemic review and meta-analysis. - ASCO. Accessed November 2, 2025. https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT136571."},{"issue":"7","key":"10.1016\/j.ctrv.2026.103111_b0525","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0530","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1078-0432.CCR-24-0106","article-title":"Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy","volume":"30","author":"Mart\u00edn","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0535","doi-asserted-by":"crossref","first-page":"12869","DOI":"10.1038\/s41598-023-40071-2","article-title":"Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype","volume":"13","author":"Orr\u00f9","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0540","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0545","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2019.05.014","article-title":"Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer","volume":"118","author":"Ochi","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0550","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0555","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41467-018-04070-6","article-title":"Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence","volume":"9","author":"Vera-Ramirez","year":"2018","journal-title":"Nat Commun"},{"issue":"31","key":"10.1016\/j.ctrv.2026.103111_b0560","doi-asserted-by":"crossref","first-page":"22113","DOI":"10.18632\/oncotarget.25197","article-title":"Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy","volume":"9","author":"Aqbi","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103111_b0565","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1038\/s41591-025-03877-3","article-title":"Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial","volume":"31","author":"DeMichele","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103111_b0570","unstructured":"Abramson Cancer Center at Penn Medicine. A Phase II Trial of Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY). clinicaltrials.gov; 2025. Accessed October 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04841148."},{"key":"10.1016\/j.ctrv.2026.103111_b0575","unstructured":"Abemaciclib Alone or in Combination with Hydroxychloroquine for the Treatment of Patients with Breast Cancer, ABBY Trial - NCI. June 23, 2016. Accessed October 17, 2025. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2021-12420."},{"key":"10.1016\/j.ctrv.2026.103111_b0580","unstructured":"Dr. Angela DeMichele. From Diagnosis to Dormancy: Changing Paradigms to Eradicate Residual Disease and Prevent Breast Cancer Recurrence. Conference presented at: Inagural Ennis Lecture; October 8, 2025."},{"key":"10.1016\/j.ctrv.2026.103111_b0585","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-PS9-03","article-title":"Abstract PS9-03: circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study","volume":"31","author":"Taranto","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103111_b0590","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","article-title":"Circulating tumor DNA validity and potential uses in metastatic breast cancer","volume":"10","author":"Amato","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0595","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-018-1049-0","article-title":"NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients","volume":"20","author":"Borgen","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103111_b0600","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103111_b0605","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0610","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-025-00783-2","article-title":"Personalized ctDNA monitoring in metastatic HR+\/HER2\u2212 breast cancer patients during endocrine and CDK4\/6 inhibitor therapy","volume":"11","author":"Fuentes-Antr\u00e1s","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103111_b0615","doi-asserted-by":"crossref","unstructured":"Cabel L, An JAR, Kim HK, et al. Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy. Npj Breast Cancer. Published online January 29, 2026. doi:10.1038\/s41523-025-00878-w.","DOI":"10.1038\/s41523-025-00878-w"},{"key":"10.1016\/j.ctrv.2026.103111_b0620","article-title":"Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial","author":"Lohmann","year":"2025","journal-title":"In: Breast Cancer\u2014Local\/Regional\/Adjuvant"},{"key":"10.1016\/j.ctrv.2026.103111_b0625","unstructured":"Home. International TILS Working Group. Accessed November 2, 2025. https:\/\/www.tilsinbreastcancer.org\/."},{"issue":"5","key":"10.1016\/j.ctrv.2026.103111_b0630","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103111_b0635","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers17162639","article-title":"Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies","volume":"17","author":"Trontzas","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103111_b0640","article-title":"Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer. Lancet Digit","volume":"7","author":"Schirris","year":"2025","journal-title":"Health"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0645","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103111_b0650","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41523-023-00536-z","article-title":"Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients","volume":"9","author":"Freeman","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103111_b0660","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.521","article-title":"MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST","volume":"41","author":"Beitsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0665","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.addr.2018.01.013","article-title":"Clinical utility of non-EpCAM based circulating tumor cell assays","volume":"125","author":"Austin","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0670","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdu018","article-title":"Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research","volume":"25","author":"Grover","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0675","first-page":"1","article-title":"Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer","volume":"3","author":"Salami","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103111_b0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237308","article-title":"Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients","volume":"15","author":"Drucker","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2026.103111_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104579","article-title":"A comprehensive review and meta-analysis of CTC isolation methods in breast cancer","volume":"206","author":"Rzhevskiy","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0690","doi-asserted-by":"crossref","first-page":"26","DOI":"10.33393\/jcb.2023.2629","article-title":"Analytical performance of the FDA-cleared Parsortix\u00ae PC1 system","volume":"12","author":"Templeman","year":"2023","journal-title":"J Circ Biomark"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0695","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13046-024-03149-x","article-title":"Identification of circulating tumor cells captured by the FDA-cleared Parsortix\u00ae PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations","volume":"43","author":"Ciccioli","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103111_b0700","doi-asserted-by":"crossref","first-page":"13930","DOI":"10.3390\/ijms241813930","article-title":"Microfluidic isolation of disseminated tumor cells from the bone marrow of breast cancer patients","volume":"24","author":"Volmer","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103111_b0705","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.20.01572","article-title":"Defining clinical utility of tumor biomarker tests: a clinician\u2019s viewpoint","volume":"39","author":"Hayes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103111_b0710","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molonc.2014.10.004","article-title":"Biomarker validation and testing","volume":"9","author":"Hayes","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0715","unstructured":"SERENA-6: ctDNA-Guided Treatment Switch to Camizestrant Before Clinical Progression Improves Outcomes in ESR1-Mutated, HR-Positive\/HER2-Negative Advanced Breast Cancer. Accessed October 16, 2025. https:\/\/dailynews.ascopubs.org\/do\/10.1200\/adn.25.300193\/full\/."},{"key":"10.1016\/j.ctrv.2026.103111_b0720","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1010","article-title":"Circulating tumor (ct)DNA monitoring of ER+\/HER2- high-risk breast cancer during adjuvant endocrine therapy","volume":"43","author":"Pusztai","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0725","unstructured":"Criterium, Inc. A Randomized, Phase II Trial of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE). clinicaltrials.gov; 2025. Accessed October 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04567420."},{"key":"10.1016\/j.ctrv.2026.103111_b0730","unstructured":"SWOG Cancer Research Network. Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study. clinicaltrials.gov; 2024. Accessed October 17, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05929768."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103111_b0735","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41467-025-56658-4","article-title":"Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay","volume":"16","author":"Elliott","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103111_b0740","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1009","article-title":"Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: first results from TBCRC 040 (the PREDICT-DNA trial)","volume":"43","author":"Hunter","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103111_b0745","unstructured":"ctDNA Levels After Neoadjuvant Therapy May Predict Breast Cancer Recurrence Better Than Pathologic Complete Response. American Association for Cancer Research (AACR). Accessed February 1, 2026. https:\/\/www.aacr.org\/about-the-aacr\/newsroom\/news-releases\/ctdna-levels-after-neoadjuvant-therapy-may-predict-breast-cancer-recurrence-better-than-pathologic-complete-response\/."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:36:36Z","timestamp":1773041796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":149,"alternative-id":["S0305737226000253"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103111","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103111"}}